Ligand Pharmaceuticals Incorporated (LGND) Market Cap & Valuation Ratios
Ligand Pharmaceuticals Incorporated (LGND) has a market cap of $6.1B, a trailing P/E of 32.3 and a price-to-sales ratio of 20.8, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LGNDLigand Pharmaceuticals IncorporatedFollow LGND — free
—
Price chart with a free account
- Market cap
- 6.1B
- P/E TTM
- 32.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LGND | 6.1 | 32.3 | 20.0 | 45.6 | 2.2% | +55% | 33% | 9% |
| PRAX | 7.1 | — | — | — | -4.3% | — | — | -68% |
| IOVA | 6.4 | — | 18.7 | — | -4.6% | +35% | -93% | -51% |
| RYTM | 6.1 | — | 24.7 | — | -1.7% | +54% | -84% | -140% |
| IMVT | 5.9 | — | — | — | -6.9% | — | — | — |
| MANE | 5.8 | — | — | — | -1.4% | — | — | -21% |
| KOD | 5.5 | — | — | — | -2.9% | — | — | — |
| CGON | 5.5 | — | 713.7 | — | -3.3% | +1030% | — | -25% |
| COGT | 5.4 | — | 615.8 | — | -5.7% | — | — | -120% |
| ORKA | 5.3 | — | — | — | -1.9% | — | — | -28% |
| MIRM | 5.2 | — | 8.9 | — | -4.4% | +44% | -135% | -224% |
| Median of these 10 | — | 24.7 | — | -3.8% | +49% | -93% | -59% |
; EV/Sales 20.0 vs. 24.7. LGND's own P/E sits at the 34th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesLigand Pharmaceuticals Incorporated — questions
- What is Ligand Pharmaceuticals Incorporated's market cap?
- $6.1B.
- What is Ligand Pharmaceuticals Incorporated's P/E ratio?
- 32.3 on trailing twelve-month earnings to 2026-06-30.
- What is Ligand Pharmaceuticals Incorporated's price-to-sales ratio?
- 20.8.
Every figure on this page comes from Ligand Pharmaceuticals Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.